Chondrosarcoma

• Age: typically over 40, in contrast to the adolescent peaks of osteosarcoma and Ewing sarcoma.
• Site: the axial skeleton and proximal long bones — pelvis, proximal femur, proximal humerus, ribs and scapula — rather than around the knee.
• Primary chondrosarcoma arises de novo; secondary chondrosarcoma arises from a pre-existing benign cartilage lesion, notably osteochondroma (particularly in hereditary multiple exostoses) and enchondroma (particularly in Ollier disease and Maffucci syndrome).
• Presentation: deep, dull pain often present for months, sometimes with a slowly enlarging mass. Pain in a known cartilage lesion is the warning sign of transformation.
• Imaging: a lytic lesion with "popcorn", rings-and-arcs or punctate chondroid calcification, cortical thickening, endosteal scalloping, and in higher grades cortical destruction with a soft-tissue mass.
• Treatment is surgical: wide en-bloc resection, because adjuvant chemotherapy and radiotherapy are largely ineffective. Prognosis follows histological grade closely.

Non-modifiable — the ones stems actually plant

• Age over 40: conventional chondrosarcoma is a tumour of middle-aged and older adults; a cartilage lesion that becomes painful in an adult is the setup examiners use.
• Pre-existing benign cartilage lesions (secondary chondrosarcoma): malignant transformation of an osteochondroma (peripheral, from the cartilage cap) or an enchondroma (central, from medullary cartilage rests). Risk is low for a solitary lesion and appreciably higher in syndromic multiplicity.
• Hereditary multiple exostoses (multiple osteochondromas): autosomal dominant loss-of-function mutations in *EXT1*/*EXT2*, which encode glycosyltransferases required for heparan sulfate synthesis and thus for hedgehog signalling control at the growth plate.
• Ollier disease (multiple enchondromatosis) and Maffucci syndrome (enchondromas plus spindle cell haemangiomas): non-hereditary mosaic *IDH1*/*IDH2* mutations. Maffucci syndrome carries the highest transformation risk and also predisposes to non-skeletal malignancy.
• Somatic IDH1/IDH2 mutation: present in a large share of conventional central chondrosarcomas and their enchondroma precursors — the molecular link between the benign and malignant lesion.
• Prior therapeutic irradiation: post-radiation sarcoma of bone arising in the treatment field after a latency of years (osteosarcoma is commoner, but chondrosarcoma occurs).

Anatomic risk

• Axial and proximal appendicular location: pelvis, proximal femur, proximal humerus, ribs, scapula. A cartilage lesion in the pelvis or scapula is treated with far greater suspicion than one in a finger, where enchondroma is common and chondrosarcoma is rare.

Modifiable factors

• Essentially none: unlike carcinoma, there is no established tobacco, dietary, or occupational contribution. The only actionable exposure is avoidable radiation, and the only actionable behaviour is surveillance of known cartilage lesions so transformation is caught early.

Not risk factors (common distractors)

• Paget disease of bone and Li-Fraumeni/retinoblastoma survivorship predispose chiefly to osteosarcoma, not chondrosarcoma.

• Cell of origin: a chondrocyte or mesenchymal precursor that retains the ability to secrete hyaline cartilage matrix. The tumour does not make osteoid — that single distinction separates it from osteosarcoma histologically and explains most of its imaging behaviour.
• IDH1/IDH2 neomorphic mutation: mutant isocitrate dehydrogenase converts isocitrate to the oncometabolite 2-hydroxyglutarate instead of α-ketoglutarate. 2-HG competitively inhibits α-KG–dependent dioxygenases, causing DNA and histone hypermethylation and a block in chondrocyte differentiation — the initiating hit in enchondroma that can progress to chondrosarcoma.
• EXT1/EXT2 loss: defective heparan sulfate proteoglycan synthesis disrupts the Indian hedgehog–PTHrP feedback loop at the physis, so chondrocytes escape the growth plate laterally and form an osteochondroma; further genetic hits in the cartilage cap yield secondary peripheral chondrosarcoma.

How the biology produces the clinical picture

• Slow growth: low mitotic index means the tumour expands over months to years. Bone has time to remodel, so the radiograph shows endosteal scalloping and reactive cortical thickening rather than the aggressive periosteal reaction (Codman triangle, sunburst) of osteosarcoma.
• Matrix mineralisation: the cartilage lobules undergo enchondral ossification and calcification at their peripheries, generating the rings-and-arcs, punctate or "popcorn" calcification that is the diagnostic signature. Higher-grade tumours are more cellular and less matrix-rich, so mineralisation is patchier and cortical destruction with a soft-tissue mass appears.
• Avascular, hypoxic, matrix-rich tissue: abundant sulfated proteoglycan limits drug diffusion, the low proliferative fraction defeats cell-cycle–dependent cytotoxics, and hypoxia blunts radiation-induced free-radical DNA damage. This is the mechanistic basis of the chemoresistance and radioresistance stated in the overview.
• Deep axial location: pelvic and scapular tumours grow silently in a compliant soft-tissue envelope, so they present late and large, often with referred or neuropathic pain from nerve compression rather than a palpable lump.
• Grade drives behaviour: metastasis, when it occurs, is haematogenous to lung; grade 1 lesions almost never metastasise, whereas dedifferentiated tumours behave like high-grade sarcoma.

Classic symptoms

• Deep, dull, aching pain: from periosteal stretching and intraosseous pressure as the slowly expanding cartilage mass remodels bone. Characteristically progressive, present at rest and at night, and not mechanical — it does not resolve with activity modification, which is why it is so often mislabelled as arthritis, bursitis or lumbar radiculopathy for months.
• Slowly enlarging firm mass: fixed, non-tender or minimally tender, arising from the bone rather than gliding over it. Chest wall lesions present as a rib or costochondral swelling.
• New pain in a known cartilage lesion: the single most important clinical sign of malignant transformation. Likewise, an osteochondroma that grows after skeletal maturity is malignant until proven otherwise.

Site-specific findings tied to mechanism

• Pelvis/sacrum: buttock or groin pain, sciatica-like radiation from lumbosacral plexus compression, and occasionally bowel or bladder symptoms from mass effect — presentation is late because the pelvis accommodates large volume.
• Proximal femur/humerus: restricted, painful range of motion; a pathologic fracture through a weakened cortex is a less common but dramatic presentation.
• Spine: axial pain with radiculopathy or, if the canal is invaded, myelopathy — an emergency.
• Skull base/craniofacial: cranial neuropathies, particularly abducens palsy with clival lesions.

Notably absent

• Systemic features: fever, weight loss and night sweats are unusual; their presence should redirect toward infection, lymphoma or Ewing sarcoma.
• Rapid onset: an explosive few-week history in a teenager around the knee is osteosarcoma or Ewing, not chondrosarcoma.

• Findings: a lytic, expansile medullary lesion with rings-and-arcs, punctate or "popcorn" chondroid matrix; endosteal scalloping; cortical thickening/expansion; in higher grades cortical breach with a soft-tissue mass.
• Features favouring malignancy over enchondroma: pain attributable to the lesion, deep endosteal scalloping involving more than about two-thirds of cortical thickness, large size, axial/pelvic location, cortical destruction, soft-tissue extension, and periosteal reaction.

Step 2 — cross-sectional imaging

• CT: best depicts matrix mineralisation, cortical integrity and pelvic anatomy.
• MRI with contrast: defines marrow and soft-tissue extent for surgical planning; cartilage is bright on T2 with lobular architecture and peripheral septal (rings-and-arcs) enhancement. In suspected transformation of an osteochondroma, MRI measures the cartilage cap — a thick cap (on the order of >2 cm in an adult) is the key alarm finding, whereas a thin cap favours a benign exostosis.
• Staging: NCCN recommends chest CT for pulmonary metastases plus whole-body bone imaging; laboratory studies are non-specific and alkaline phosphatase is typically normal, unlike osteosarcoma.

Histology and grading

• Grade 1 to 3 by cellularity, nuclear size and atypia, mitoses, myxoid change and entrapment of host bone; grade predicts recurrence and metastasis better than any other variable. WHO now designates grade 1 lesions of the appendicular skeleton atypical cartilaginous tumour.
• Variants: dedifferentiated (abrupt bimorphic junction of low-grade cartilage with high-grade non-cartilaginous sarcoma), mesenchymal (HEY1-NCOA2 fusion), clear cell, periosteal.
• Staging systems: AJCC TNM with grade, and the surgical Enneking (MSTS) system.

Immediate issues first

• Impending or actual pathologic fracture and spinal cord compression are handled before oncologic surgery — stabilisation, and for cord compression urgent decompression, corticosteroids (dexamethasone) and neurosurgical input.
• Refer before you cut: NCCN advises that a suspected primary bone sarcoma be evaluated at a multidisciplinary sarcoma centre before biopsy or any surgical manipulation.

Definitive management is surgical — this is the answer on the exam

• Wide en-bloc resection with negative margins: the standard for conventional intermediate- and high-grade tumours and for essentially all pelvic, scapular and axial disease, per NCCN Bone Cancer guidelines. Limb salvage with reconstruction is preferred over amputation when a wide margin is achievable.
• Atypical cartilaginous tumour / grade 1 of the extremity: NCCN accepts less morbid options — intralesional curettage with local adjuvant and reconstruction, or serial imaging surveillance for asymptomatic lesions. Intralesional treatment is not acceptable for higher-grade or axial tumours.

Systemic therapy — the exception, not the rule

• Conventional chondrosarcoma: cytotoxic chemotherapy and conventional radiotherapy provide no reliable benefit; the avascular, proteoglycan-rich, slowly proliferating matrix defeats both. Do not choose neoadjuvant chemotherapy as the next step (that is the osteosarcoma/Ewing pathway).
• Mesenchymal chondrosarcoma: NCCN supports Ewing-type multi-agent chemotherapy — an anthracycline plus alkylator regimen (vincristine, doxorubicin, cyclophosphamide alternating with ifosfamide and etoposide).
• Dedifferentiated chondrosarcoma: treated as high-grade sarcoma, often with osteosarcoma-style regimens (doxorubicin plus cisplatin), acknowledging poor response.
• Radiotherapy: reserved for unresectable or incompletely resected axial and skull-base disease, where high-dose charged-particle (proton/carbon-ion) therapy is used because conventional photon doses are inadequate.
• Metastatic/unresectable disease: metastasectomy for resectable lung metastases; otherwise clinical trial — including IDH1-directed inhibitors — is the preferred NCCN option.

Contraindicated or wrong answers

• Unplanned excision or curettage of a high-grade lesion, biopsy through an uninvolved compartment, and reliance on chemoradiation as primary therapy.

Disease-related

• Local recurrence: the dominant failure mode, driven by inadequate margins in the anatomically constrained pelvis and spine. Signals itself as new pain or a growing mass at the operative site; recurrent tumour frequently returns at a higher grade.
• Tumour seeding of the biopsy tract: iatrogenic implantation of cartilage cells along a poorly planned needle path — preventable, and the reason biopsy is placed in line with the future incision.
• Pathologic fracture: cortical replacement and endosteal scalloping weaken torsional strength; abrupt pain and deformity after trivial load.
• Pulmonary metastasis: haematogenous, grade-dependent, and typically late; screened for with chest CT.
• Dedifferentiation: a low-grade cartilage tumour acquires a high-grade non-cartilaginous sarcomatous component — clinically a sudden change in tempo, rapidly enlarging mass and destructive lysis in a previously indolent lesion. Prognosis is poor.
• Spinal cord or cauda equina compression from a vertebral or sacral lesion — a neurosurgical emergency; progressive weakness, sensory level, or bowel/bladder dysfunction mandates immediate MRI, corticosteroids and decompression.
• Neurovascular compression in the pelvis: lumbosacral plexopathy, iliac vein compression with limb swelling and deep vein thrombosis, and hydronephrosis from ureteric involvement.

Treatment-related

• Surgical morbidity: internal or external hemipelvectomy and large limb-salvage reconstructions carry high rates of wound breakdown, deep infection, prosthetic/allograft failure, nonunion, and permanent functional loss; venous thromboembolism risk is substantial. Massive intraoperative haemorrhage during pelvic resection is an intraoperative emergency.
• Radiotherapy (axial/skull-base): cranial neuropathy, brainstem or optic injury, osteoradionecrosis, and late radiation-induced sarcoma.
• Chemotherapy in the variants that receive it: anthracycline-induced dilated cardiomyopathy (dose-dependent, falling ejection fraction on surveillance echocardiography), cisplatin nephrotoxicity and irreversible high-frequency ototoxicity, ifosfamide haemorrhagic cystitis (prevented with mesna) and encephalopathy, and myelosuppression with neutropenic fever — an emergency requiring immediate empiric broad-spectrum antibiotics per IDSA febrile neutropenia guidance.

• The triad that names the diagnosis: adult over 40 + pelvis/proximal femur/shoulder girdle/ribs + lytic lesion with "popcorn" or rings-and-arcs chondroid calcification. Around the knee in a teenager is osteosarcoma; diaphysis with onion-skin periosteal reaction in a child is Ewing sarcoma.
• Single best next step for a new painful cartilaginous bone lesion: plain radiograph first, then MRI, then referral to a sarcoma centre for biopsy — never an unplanned excision or curettage, and never neoadjuvant chemotherapy.
• The association examiners love: malignant transformation in hereditary multiple exostoses, Ollier disease and Maffucci syndrome. Maffucci = enchondromas + spindle cell haemangiomas, and carries the highest risk. IDH1/IDH2 mutation is the molecular thread linking enchondroma to conventional chondrosarcoma; EXT1/EXT2 underlies osteochondromas.
• Transformation warning signs: new pain in a previously silent cartilage lesion, growth of an osteochondroma after skeletal maturity, and a thickened cartilage cap on MRI.
• Treatment is a scalpel, not a drug: wide en-bloc resection with negative margins. Conventional chondrosarcoma is chemoresistant and radioresistant because the tumour is hypovascular, matrix-dense and slowly proliferating. Exceptions worth knowing: mesenchymal (young patients, HEY1-NCOA2 fusion, Ewing-type chemotherapy) and dedifferentiated (bimorphic histology, dismal prognosis).
• Grade is the prognosis: grade 1 (WHO atypical cartilaginous tumour in the extremities) rarely metastasises and may be curetted or watched; high grade metastasises haematogenously to lung.
• Lab distractor: alkaline phosphatase is usually normal — an elevated ALP in a bone-tumour stem points toward osteosarcoma or Paget disease.
• Histology distractor: chondrosarcoma makes cartilage matrix, never osteoid. Malignant cells producing osteoid define osteosarcoma, no matter how much cartilage is also present.
• Clear cell chondrosarcoma sits in the epiphysis of the proximal femur or humerus and is the adult mimic of chondroblastoma.